The calcium channel blocker Cav2.1 combined with amyloid beta monoclonal antibodies may reduce the occurrence of ARIA‐E

Abstract

Background: Amyloid‐targeting monoclonal antibodies were approved by FDA in the treatment of Alzheimer’s disease, some patients have experienced adverse reactions related to amyloid‐associated imaging abnormalities, including both cerebral edema‐type(ARIA‐E) and cerebral hemorrhage‐type(ARIA‐H), which significantly imp

The paper